Gilead Gets Approved for Accelerated Assessment of Hep C Drug

Share

Follow Us

Print this page

Gilead Sciences receives EU green light for hepatitis C drug assessment

April 1, 2014 in Pharmaceutical Company Product News

Gilead Sciences has announced that the European Medicines Agency (EMA) has ratified its application for the assessment of a new treatment of chronic hepatitis C virus (HCV) infections.

The regulator has accepted the company’s marketing authorisation application for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir (LDV) 90 mg and the nucleotide analogue polymerase inhibitor sofosbuvir (SOF) 400 mg, for the treatment of chronic HCV genotype 1.

Continue reading this entire article:
http://www.zenopa.com/news/801708681/gilead-sciences-receives-eu-green-light-for-hepatitis-c-drug-assessment

Download Our Free Reports

Inside you'll discover:

• Things You May Not Know About Hepatitis C
• 7 Liver Detox SUPER Foods Your Doctor Isn't Telling You About
• 5 Dangerous Foods That Will Wreak Havoc On Your Liver
• A free "Mystery" Gift Valued at $9.99

Email address

Download Now

You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.